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Abstract 
Purpose: The incidence of non-melanoma skin cancer (NMSC) has been increasing over the past 30 years. Basal 
cell carcinoma and squamous cell carcinoma are the two most common subtypes of NMSC. The aim of this study 
was to estimate tumour control, toxicity, and aesthetic events in elderly patients treated with high-dose-rate (HDR) 
brachytherapy (BT) using Valencia applicator. 
Material and methods: From January 2012 to May 2015, 57 lesions in 39 elderly eligible patients were enrolled. All 
the lesions had a diameter ≤ 25 mm (median: 12.5 mm) and a depth ≤ 4 mm. The appropriate Valencia applicator, 2 or 
3 cm in diameter was used. The prescribed dose was 40 Gy in 8 fractions (5 Gy/fraction) in 48 lesions (group A), and 
50 Gy in 10 fractions (5 Gy/fraction) in 9 lesions (group B), delivered 2/3 times a week. The biological effective dose 
(BED) was 60 Gy and 75 Gy, respectively. 
Results: After median follow-up of 12 months, 96.25% lesions showed a complete response and only two cases 
presented partial remission. Radiation Therapy Oncology Group – European Organization for Research and Treat-
ment of Cancer (RTOG/EORTC) G 1-2 acute toxicities were observed in 63.2% of the lesions: 56.3% in group A and 
77.7% in group B. Late G1-G2 toxicities was observed in 19.3% of the lesions: 18.8% in group A and 22.2% in group B, 
respectively. No G3 or higher acute or late toxicities occurred. In 86% of the lesions, an excellent cosmetic result was 
observed (87.5% in group A and 77.8% in group B). Six lesions had a good cosmetic outcome and only 2.3% presented 
a fair cosmetic impact. 
Conclusions: The treatment of NMSC with HDR-BT using Valencia surface applicator is effective with excellent 
and good cosmetics results in elderly patients. The hypofractionated course appears effective and no statistical differ-
ences were observed between the two groups analysed. 
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Purpose
The incidence of skin cancer has been increasing over 
the past 30 years and currently 2-3 million new cases are 
diagnosed worldwide every year. Non-melanoma skin 
cancer (NMSC) is the most common skin malignancy 
(95%) and in recent years its incidence has been increasing 
rapidly, even in young populations [1, 2]. The develop-
ment of NMSC is due to a combination of environmental, 
genetic, and phenotypic factors [3, 4]. Basal cell carcino-
ma (BCC) and squamous cell carcinoma (SCC) are the 
two most common subtypes: about 75-80% of all NMSC 
are characterized by the presence of BCC, 15-20% of these 
malignancies present SCCs, while 1% show a mixed 
phenotype [5]. There are different treatment options for 
NMSC such as surgery, cryotherapy, laser therapy (rec-
ommended only for shallow and early SCC), topical 
chemotherapy, photodynamic therapy, and radiotherapy 
(RT). Surgical excision is the most frequent treatment due 
to its low rates of recurrence, reported less than 5% [6, 
7, 8, 9, 10]. In addition, RT is often used to treat NMSC 
and – specifically – different techniques can be used such 
as superficial X-rays, electron beams, megavoltage pho-
tons, and low-dose-rate (LDR) or high-dose-rate (HDR) 
brachytherapy (BT). Usually, the treatment options are 
chosen based on the institutional resources and the spe-
cialist’s experiences. The introduction of new devices us-
able with the equipment of HDR-BT and the commercial-
ization of electronic BT has attracted considerable interest 
in the BT treatment of small skin tumours. The Valencia 
applicator (Nucletron, an Elekta company, Stockholm, 
Sweden) is a new superficial device used in BT to treat 
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skin lesions, and has been projected to be used with the 
HDR afterloader microSelectron (Nucletron, an Elekta 
company, Stockholm, Sweden) [11, 12, 13, 14]. The design 
of Valencia applicators is based on Leipzig applicators, 
adding to them a flattening filter to improve the dose rate 
distributions’ homogeneity and limit the penumbra. Re-
garding the dimensions, there are two sizes of Valencia 
applicators: 2 cm (VH2) and 3 cm (VH3) in diameter. The 
use of Valencia applicators is recommended for super-
ficial tumours (less than 4 mm depth) with a maximum 
diameter of 25 mm due to guaranteeing adequate tumour 
coverage. The reinforced shielding at the back of the skin 
radiation applicator adds to patient safety during treat-
ment, and plastic caps on the applicator help to avoid 
over-dosage and assist with correct applicator position-
ing [11, 12, 13]. The design of this applicator allows us 
to focus the radiation on the target while normal tissue 
irradiation is minimized, leading to safer treatment and 
a decrease in side effects in normal tissue [11, 12, 13, 14, 
15, 16, 17, 18, 19, 20, 21, 22, 23, 24]. 
The aim of this study was to retrospectively estimate 
tumour control, toxicity, and cosmetic events in two case 
series of elderly patients, affected by NMSC treated with 
HDR BT using a Valencia applicator.
Material and methods 
Patients’ eligibility 
We retrospectively evaluated 57 lesions in 39 elderly 
patients treated with HDR-BT using a Valencia applica-
tor. All the patients presented NMSC (confirmed by his-
tological examination) and were treated at the Depart-
ment of Radiotherapy, University of Pisa. All the enrolled 
patients were older than 70 years. Patients aged less than 
70 years with a diagnosis of melanoma were excluded 
from the study; patients showing diameter lesions great-
er than 25 mm and a depth of more than 4 mm by clinical 
and imaging evaluation were also excluded. In this study, 
NMSC patients who were surgically treated or who had 
relapses or recidivisms were also included. 
Furthermore, any patients who were unable to collabo-
rate and stayed fixed during the treatment were excluded 
from the study. The cohort’s characteristics are shown in 
Table 1 and a consort flow diagram is shown in Figure 1. 
Treatment procedure 
All the lesions for the selected cases were limited to 
a maximum depth of 4 mm and a diameter equal to or 
less than 25 mm. This limitation was necessary to keep 
the skin dose at acceptable levels because the percentage 
depth dose of the 192Ir Valencia applicators has a gradient 
of about 10% per mm [14]. The planning target volume 
Table 1. Patients and lesion characteristics 
Demographics Number %
Patient characteristics
     Age (years)
     Median 84
     Minimum 70
     Maximum 96
     Sex
     Male 24 61
     Female 15 39
Histology
Basal cell carcinoma 44 77.2
Squamous cell carcinoma 12 21.1
Kaposi’s sarcoma 1 1.7
Lesion diameter (mm)
Minimum 3 mm
Maximum 25 mm
Median 12.5 mm
Lesion location
     Head and Neck 46 80.7
     Scalp 18 31.6
     Face 15 26.3
     Nose 8 14
     Ear 3 5.3
     Neck 2 3.5
     Trunk 7 12.3
     Extremity 4 7
Fig. 1. Consort flow diagram 
69 lesions in 51 pts affected  
by NMSC candidate at tratment  
with HDR-BT using Valencia  
applicatiors were analyzed
65 lesions in 47 pts affected  
by NMSC were treated  
with HDR-BT using Valencia  
applicators
57 lesions in 39 pts were eligibly  
for the study
•  45 lesions were treated only with 
HDR-BT
•  12 lesions were treated surgically 
before HDR-BT
4 pts (2 male, 2 female) were  
excluded because couldn’t stay fixed
8 pts (3 male, 5 female) were aged  
less than 70 years
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was defined as a BCC and SCC macroscopic lesion (gross 
tumour volume) adding an adequate margin of 5 mm. 
According to Brodland et al.’s [8] data and based on the 
other HDR-BT studies [18, 19, 20, 23, 24, 25, 26, 27, 28, 
29, 30, 31, 32, 33, 34, 35, 36], a margin of 5 mm for BCC 
and SCC lesions appears to be adequate. The maximal 
diameter able to be treated using Valencia applicators is 
25 mm, since the largest surface applicator has an inner 
diameter of 30 mm. This is possible due to improvements 
in the lateral homogeneity and flatness of the Valencia 
applicator compared to the Leipzig applicators. The val-
ues of the penumbra (80-20%) are significantly improved 
from the Leipzig (6.2-9.5 mm) to the Valencia applicators 
(1.9 mm). As such, the useful treatment area of the Va-
lencia applicator is larger and this allows a 5 mm mar-
gin for microscopic diseases and set-up errors in lesions 
with a diameter ≤ 25 mm [11, 12, 14]. The gross tumour 
volume (GTV) was generally visually assessed; howev-
er, ultrasound imaging or a CT scan were, in a few cases 
(n = 7 lesions), used to determine the real depth and lesion 
dimensions. An appropriate Valencia applicator – 2 or 3 
cm of diameter – was chosen based on the diameter lesion 
for an optimal dose rate distribution to the GTV [14, 21]. 
The treatment dose prescription was 40 Gy in eight frac-
tions (5 Gy for each fraction daily) in 48 lesions (group A) 
and 50 Gy in 10 fractions (5 Gy for each fraction daily) in 
nine lesions (group B). The total dose was chosen based 
on the lesion dimensions, age, and performance status. 
The dose prescription was delivered as two/three fractions 
a week, with a minimum interval of 48 hours between frac-
tions. The treatment characteristics are shown in Table 2. 
The Biological Effective Dose (BED) was (BED α/β:10) 
60 Gy in group A and (BED α/β:10) 75 Gy in group B. All 
the patients were immobilized during the treatment and 
a skin marker delineating the outside applicator circum-
ference was used in some patients to ensure reproducible 
treatment conditions. The immobilization was achieved 
in some cases (such as patients with head and neck le-
sions) using an articulated arm device provided by Nu-
cletron; in less difficult cases, the methods of immobili-
zation were tape or a thermoplastic mask. The treatment 
was effectuated under the direct supervision of the radi-
ation oncologist for accurate applicator positioning and 
dose delivery. As a precaution, it was recommended for 
all patients to not wear any make-up and in addition they 
were continuously monitored during treatment by video 
camera and audio connection with a treatment room to 
ensure the immobility of the patient. 
End points 
The end points chosen for this study were analysis of 
efficacy, safety, toxicity, and cosmetic outcomes in elder-
ly patients treated with HDR-BT using Valencia applica-
tors. Acute and chronic toxicities were evaluated in both 
groups according to the Radiation Therapy Oncology 
Group (RTOG) and the European Organization for Re-
search and Treatment of Cancer (EORTC) scales by clin-
ical evaluation during and after treatment. The cosmetic 
results were estimated at each follow-up visit based on 
the radiation therapy oncology group scale (Table 3) [25]. 
Results 
Patient and treatment characteristics 
Between January 2012 and May 2015, 57 lesions in 
a total of 39 patients affected by NMSC were treated with 
HDR-BT using a Valencia surface applicator. Of them, 
25 patients (61%) were male and 14 (39%) were female. 
Twelve lesions were treated as a supplementary therapy 
after surgery treatment (Figure 1). The median age of the 
patients treated was 84 years (DS ± 7.84) with a wide range 
from 70 to 96 years. Most of lesions (77.2%) histologically 
were BCC: 21.1% were SCC and one lesion was Kaposi’s 
sarcoma. In addition, 46 lesions (80.7%) were located on the 
head and the neck: seven lesions (12.3%) on the trunk, and 
four lesions (7%) were found on the extremities. The me-
dian diameter of the lesion was 12.5 mm (range: 3-25) and 
all lesions had a depth of less than 4 mm. Table 1 describes 
the patient and lesion characteristics. During the treatment, 
we used 29 applicators with a diameter of 3 cm and 28 
applicators with a diameter of 2 cm, as shown in Table 2. 
The median follow-up was 12 months (range: 3-29 months). 
Efficacy 
After 12 months median follow-up, 55 lesions (96.5%) 
completely regressed and only two lesions persisted: one 
lesion was histologically diagnosed as SCC, located in 
Table 2. Treatment characteristics 
Treatment characteristics Number  
of lesions
BCC SCC and 
Kaposi’s  
sarcoma
Total dose (Gy; BED α/β:10)
50 Gy (BED75) 9 (16%) 6 3
40 Gy (BED60) 48 (84%) 38 10
Applicator size (mm)
Valencia 20 28 (49%) 20 8
Valencia 30 29 (51%) 24 5
BED – biological effective dose, BCC – basal cell carcinoma, SCC – squamous 
cell carcinoma  
Table 3. Cosmetic rating scale [25] 
Excellent No changes to slight atrophy or pigment change or 
slight hair loss or no changes to slight induration 
or loss of subcutaneous fat 
Good Patch atrophy, moderate telangiectasia, and total 
hair loss; moderate fibrosis but asymptomatic;
slight field contracture with less than 10% linear 
reduction 
Fair Marked atrophy and gross telangiectasia; severe 
induration or loss of subcutaneous tissue; field
contracture greater than 10% linear measurement 
Poor Ulceration or necrosis
Journal of Contemporary Brachytherapy (2015/volume 7/number 6)
Durim Delishaj, Concetta Laliscia, Bruno Manfredi, et al.440
the trunk, and received a total dose of 50 Gy delivered in 
10 fractions. The second lesion was instead diagnosed as 
BCC, and it was located in the face, treated with a total 
dose of 40 Gy in eight fractions. In both lesions, the depth 
of the lesion was less than 4 mm and the tumour diameter 
was less than 25 mm. No recurrences or disease persis-
tence were detected during the follow-up and there was 
no difference between the two groups (Table 4). 
Adverse events and cosmetic results 
The treatment was well tolerated in all cases. The most 
common early side-effects were erythema, rash dermati-
tis, and pruritus, which occurred in 63.2% of the patients. 
The highest skin acute toxicity was Grade 1 RTOG/EO-
RTC [25] and occurred in 58% of the lesions: 56.3% of the 
lesions in group A and 66.7% of the lesions in group B. 
Only three (5.3%) lesions had Grade 2 toxicities: 4.1% in 
group A and 11.1% in group B. All the cases of G1-G2 
acute toxicity were resolved with topical treatment. No 
statistically differences were observed between the two 
groups analysed regarding acute toxicities (p = 0.269). 
On the subject of late toxicities, there were 11 cases of G1-
G2 late toxicities: G1 was observed in 16.7% of the lesions in 
group A and 22.2% of the lesions in group B. Only one case 
of G2 late toxicity in group A was observed. They were all 
resolved with adequate local treatment and no statistical dif-
ferences existed between the two groups (p = 0.404). There 
were no Grade 3 or higher acute or late toxicities. 
The cosmetic results were evaluated at each follow-up 
visit based on the radiation therapy oncology group scale 
(Table 3) [25]. An excellent cosmetic result was observed 
in 86% of lesions: 87.5% in group A and 77.8% in group B 
(Table 4 results; Figure 2). 
About 12.3% of the lesions had good cosmetic re-
sults (moderate atrophy in three patients and moderate 
asymptomatic fibrosis in another four): five (10.4%) in 
group A and two (22.2%) in group B. 
Only one patient 1.7% (in group A) presented a fair 
cosmetic result. There was no correlation between the 
two groups and excellent cosmetic results (p = 0.458). Fi-
nally, there were no cases of poor cosmetic results. 
With univariate statistical analysis of local control 
prognostic factors, only the total dose prescribed was sta-
tistically significant (p = 0.001), leading to improve local 
control. This means that with increasing the total dose 
– with an equal dose for fractions – local control proba-
bility is improved. Other prognostic factors at regression 
univariate analysis, such as lesion dimensions, histology, 
and surgery did not lead to improved disease local con-
trol (Table 5). 
The statistical analyses data were performed with 
SPSS version 22 (SPSS Inc. SPSS® Chicago, IL, USA). All 
the variables were described by statistical characteris-
tics: categorical data were described by frequency and 
percentage, whereas continuous data were described by 
mean and range. The study of local control prognostic 
factors such as lesion dimensions, histology type, sur-
gery, and total dose was performed through the use of 
a univariate generalized linear model. The results of the 
regression model were calculated by a Wald test and 
Table 4. Results 
All lesions Group A
(40 Gy in 8 faction)
Group B
(50 Gy in 10 fraction )
Response to treatment
Complete response 55 (96.25 %) 47 8
Partial response 2 (3.5 %) 1 (BCC) 1 (SCC)
Recurrence 0 0 0
Acute toxicity 36 (63.2%) 29 (60.4%) 7 (77.7 %)
Grade 1 33 (58 %) 27 (56.3%) 6 (66.7)
Grade 2 3 (5.3%) 2 (4.1%) 1 (11.1%)
Grade 3 0 0 0
Late toxicities 11 (19.3%) 9 (18.8 %) 2 (22.2 %)
Grade 1 10 (17.5 %) 8 (16.7 %) 2 (22.2%)
Grade 2 1 (1.9 %) 1 (2.1  %) 0
Grade 3 0 0 0
Cosmetic results
Excellent 49 (86 %) 42 (87.5%) 7 (77.8%)
Good 7 (12.3 % 5 (10.4 %) 2 (22.2%)
Fair 1 (1.7%) 1 (2.1 %) 0
Poor 0 0 0
Journal of Contemporary Brachytherapy (2015/volume 7/number 6)
Non-melanoma skin cancer treated with HDR Brachytherapy and Valencia applicator 441
expressed using the regression coefficients. Differences 
were considered significant at p < 0.05. 
Discussion 
Surgery is often the primary treatment for NMSC 
lesions for the low rates of recurrence reported [6, 7, 8, 
9, 10]. However, surgical treatment is an invasive proce-
dure and in elderly patients is not always feasible because 
of comorbidities, performance status, or lesion location 
(near the eyes, nose, and on facial skin). Typically, RT is 
the treatment of choice in this class of patients since sur-
gery might be accompanied with functional or cosmetic 
deficits. The development of new devices for small skin 
tumour treatment and the introduction of commercial 
electronic BT, have attracted considerable interest for BT 
as a skin cancer treatment. Despite the new technologies 
available, few studies have focused on the treatment of 
NMSC with HDR-BT. Köhler et al. [13] in 1999 described 
the outcome of 520 lesions treated with HDR-BT using 
Leipzig applicators. The dose prescribed was 30-40 Gy in 
5-10 fractions, and after 10 years follow-up local control 
was 92% of the cases; only G1-G2 late and acute toxicities 
were observed. In the study was included Kaposi’s sarco-
ma, melanomas, and skin metastases. One year later, Guix 
et al. [24] reported the results of 236 NMSC lesions treat-
ed with HDR-BT using custom-made surface moulds. At 
five years median follow-up, local control was 98%. In ad-
dition, Gauden et al. [31] published the data of 236 lesions 
using Leipzig applicators. The total dose prescribed was 
36 Gy in 12 fractions and the local control was 98% after 
36 months follow-up. No G3 or higher late or acute tox-
icities were observed. Recently, Bhatnagar et al. [32] and 
Tormo et al. [36] published the results of a hypofractionat-
ed course (using Valencia applicators and HDR electronic 
BT with surface applicators, respectively), which resulted 
in excellent local control, cosmetic results, and very low-
grade toxicities after a median follow-up of 47 months 
and 12 months, respectively. Table 6 describes some pre-
vious studies of HDR-BT for NMSC. 
We showed in our study that the treatment of 57 
NMSC lesions with HDR-BT using Valencia surface ap-
plicator with doses of 50 Gy and 40 Gy in 10 and eight 
fractions is effective and safe in elderly patients. In this 
study, the BED was evaluated and in particular the BED 
values were BED 60 in group A and BED 75 in group B. 
Biological effective dose is an inherent part of the linear 
quadratic (LQ) model of radiation effects, and estimates 
the true biological dose delivered by a particular combi-
nation of dose per fraction and total dose to a given tissue 
characterized by a specific a/b ratio. It is calculated by the 
equation BED = nd [1 + d(α/β)], where n = the number of 
fractions, d = the dose/fraction, and α/β = radio-sensitivi-
ty coefficients at the dose at which the linear and quadrat-
ic components (for early or late cell damage, respectively) 
of cells killed are equal [33, 34]. 
Fig. 2. An example of complete response (B) after nine months of treatment of NMSC with HDR-BT using a Valencia applicator
A B
Table 5. Univariate analysis of local control prognostic factors
Factor Intercept B* Wald test p value
Lesion dimension (3-25 mm) 11,663 –0,31 0,034 0,854
Histology (SCC, SCC, Kaposi’s sarcoma) 11,949 –1,656 2,015 0,156
Surgery (yes, no) 8,484 2,044 1,062 0,303
Total dose (40 Gy, 50 Gy) 10,021 7,979 10,799 0,001
*Regression coefficient; BCC – basal cell carcinoma, SCC – squamous cell carcinoma
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The a/b ratios vary based on the tumour type. For 
example, squamous cell cancers with high cell prolifer-
ation are characterized by 10-30 α/β ratio, while breast 
cancer shows lower values (4-5 Gy) [34] as well in pros-
tate cancer (0.8-2.5 Gy) [35] and melanoma malignancies 
[34]. For NMSC, the alpha/beta ratios are approximately 
10 Gy [34]. From the previous equation, it is evident that 
the BED will increase proportionally to the dose per frac-
tion and inversely proportional to the α/β ratio. If the to-
tal dose is kept constant, the BED will increase if the dose 
per fraction is increased [33, 34, 35]. For these reasons, it is 
important to perform BED calculations before clinical de-
cisions since different histological classes of cancers have 
different a/b ratios, leading to different clinical responses, 
despite the total dose not change. The hypofractionated 
course (40-50 Gy in 8-10 fractions delivered two/three 
time a week with a minimum interval of 48 hours between 
fractions) appears to be effective with very good local 
control, excellent cosmetic results, and acceptable toxic-
ities in elderly patients. No recurrences after 12 months 
follow-up have been observed at the time of the analysis, 
and overall, the treatment was very well tolerated with no 
evidence of Grade 3 or higher toxicities. 
The limitation of this study compared with studies 
of more established treatments for NMSC was the rela-
tively short follow-up and small number of patients due 
to the age of the patients (mean age 84 years) aa well as 
comorbidities. In particular, patients exhibited a low life 
expectancy and important comorbidities such as cardio-
vascular and pulmonary complications (due to age rather 
than therapy), which did not allow a long follow-up in all 
patients. Non-melanoma skin cancer patients will contin-
ue to be followed and additional patients will be enrolled 
for further study of the outcomes using HDR-BT. 
Conclusions 
In our study, the treatment of NMSC with HDR-BT 
using Valencia surface applicator was effective and safe 
in elderly patients. After 12 months follow-up, no recur-
rences were observed and the treatment was very well 
tolerated with no Grade 3 or higher acute or late toxici-
ties. In addition, we found excellent and good cosmetics 
results. Valencia applicators provide a simple, safe, quick, 
and easy alternative for skin cancer treatment compared 
with more invasive methods, such as surgery or cryother-
apy, in this subset of patients. Overall, the hypofraction-
ated course appears effective with very good local disease 
control; moreover, this cost effective therapy shows high 
compliance and a feasible outpatient treatment regimen, 
essential in elderly patients. No statistical differences were 
observed between the two groups analysed regarding ef-
ficacy, acute toxicities, late toxicities, and cosmetic results. 
Acknowledgments 
The authors declare that an abstract with preliminary 
data (a total of 52 lesions) has been accepted as a poster 
(abstract  number 3 316) at 18th ECCO – 40th ESMO Euro-
pean Cancer Congress  held in Vienna, Austria, 25th – 29th 
September 2015. 
Disclosure 
Authors report no conflict of interest. 
References 
1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic re-
view of worldwide incidence of nonmelanoma skin cancer. 
Br J Dermatol 2012; 166: 1069-1080. 
2. Eisemann N, Waldmann A, Geller AC et al. Non-melanoma 
skin cancer incidence and impact of skin cancer screening on 
incidence. J Invest Dermatol 2014; 134: 43-50. 
3. Kricker A, Armstrong BK, English DR et al. Does intermit-
tent sun exposure cause basal cell carcinoma. A case-control 
study in Western Australia. Int J Cancer 1995; 60: 489-494. 
4. Rosso S, Zanetti R, Martinez C et al. The multicentre south 
European study ‘Helios’. I: Different sun exposure patterns 
in the aetiology of basal cell and squamous cell carcinomas 
of the skin. Br J Cancer 1996; 73: 1440-1446. 
5. Katalinic A, Kunze U, Schafer T. Epidemiology of cutaneous 
melanoma and non-melanoma skin cancer in Schleswig-Hol-
stein, Germany: incidence, clinical subtypes, tumour stages 
and localization (epidemiology of skin cancer). Br J Dermatol 
2003; 149: 1200-1206. 
6. Caresana G, Giardini R. Dermoscopy-guided surgery in 
basal cell carcinoma. J Eur Acad Dermatol Venereol 2010; 24: 
1395-1399. 
7. Smeets NW, Kuijpers DI, Nelemans P et al. Mohs’ micro-
graphic surgery for treatment of basal cell carcinoma of the 
face – results of a retrospective study and review of the litera-
ture. Br J Dermatol 2004; 151: 141-147. 
8. Brodland DG, Zitelli JA. Surgical margins for excision of pri-
mary cutaneous squamous cell carcinoma. J Am Acad Derma-
tol 1992; 27: 241-248. 
9. Macfarlane L, Waters A, Evans A et al. Seven years’ experi-
ence of Mohs micrographic surgery in a UK centre, and de-
velopment of a UK minimum dataset and audit standards. 
Clin Exp Dermatol 2013; 38: 262-269. 
10. Chren MM, Torres JS, Stuart SE et al. Recurrence after treat-
ment of non melanoma skin cancer: a prospective cohort 
study. Arch Dermatol 2011; 147: 540-546. 
11. Pérez-Calatayud J, Granero D, Ballester F et al. A dosimetric 
study of the Leipzig applicators. Int J Radiat Oncol Biol Phys 
2005; 62: 579-584. 
12. Niu H, Hsi WC, Chu JC et al. Dosimetric characteristics of the 
Leipzig surface applicators used in the high dose rate brachy 
radiotherapy. Med Phys 2004; 31: 3372-3327. 
13. Köhler-Brock A, Prager W, Pohlmann S et al. The indications 
for and results of HDR afterloading therapy in diseases of the 
skin and mucosa with standardized surface applicators (the 
Leipzig Applicator). Strahlenther Onkol 1999; 175: 170-174. 
14. Granero D, Perez-Calatayud J, Ballester F et al. Radiation 
leakage study for the Valencia applicators. Phys Med 2013; 
29: 60-64. 
15. Granero D, Pérez-Calatayud J, Gimeno J et al. Design and 
evaluation of a HDR skin applicator with flattening filter. 
Med Phys 2008; 35: 495-503. 
16. Kowalik L, Lyczek J, Sawicki M et al. Individual applicator 
for brachytherapy for various sites of superficial malignant 
lesions. J Contemp Brachytherapy 2013; 5: 45-49.
17. Hwang IM, Lin SY, Lin LC et al. Alternative effective modal-
ity of  Leipzig applicator with an electron beam for the treat-
ment of superficial malignancies. Nuc Inst Meth A 2003; 508: 
460-466. 
18. Ghaly M, Birnes R, Musmacher J et al. HDR brachytherapy 
with standardized surface applicators (the Leipzig applicator) 
as an alternative, radiotherapy treatment for superficial malig-
nant skin lesions. Int J Radiat Oncol Biol Phys 2006; 66: S719-S720. 
Journal of Contemporary Brachytherapy (2015/volume 7/number 6)
Durim Delishaj, Concetta Laliscia, Bruno Manfredi, et al.444
19. Svoboda V, Kovarik J, Morris F. High dose-rate microselec-
tron molds in the treatment of skin tumors. Int J Radiat Oncol 
Biol Phys 1995; 31: 967-972. 
20. Ghaly M, Zinkin H, Dannenberg M et al. HDR brachythera-
py with Standardized Surface Applicators in the Treatment 
of Superficial Malignant Skin Lesions. Int J Radiat Oncol Biol 
Phys 2008; 72: S505-S506. 
21. Khan L, Choo R, Breen D et al. Recommendations for CTV 
margins in radiotherapy planning for non melanoma skin 
cancer. Radiother Oncol 2012; 104: 263-266. 
22. Lovett RD, Perez CA, Shapiro SJ et al. External radiation of 
epithelial skin cancer. Int J Radiat Oncol Biol Phys 1990; 19: 
235-242. 
23. Alam M, Nanda S, Mittal BB et al. The use of brachytherapy 
in the treatment of nonmelanoma skin cancer: a review. J Am 
Acad Dermatol 2011; 65: 377-388. 
24. Guix B1, Finestres F, Tello J et al. Treatment of skin carcino-
mas of the face by high dose rate brachytherapy and custom 
made surface molds. Int J Radiat Oncol Biol Phys 2000; 47: 95-
102. 
25. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation 
Therapy Oncology Group (RTOG) and the European Orga-
nization for Research and Treatment of Cancer (EORTC). Int 
J Radiat Oncol Biol Phys 1995; 31: 1341-1346. 
26. Fabrini MG, Perrone F, De Liguoro M et al. High dose rate 
brachytherapy in a large squamous cell carcinoma of the 
hand. Brachytherapy 2008; 7: 270-275. 
27. Ballester-Sánchez R, Pons-Llanas O, Llavador-Ros M et al. 
Depth determination of skin cancers treated with superfi-
cial brachytherapy: ultrasound vs. histopathology. J Contemp 
Brachytherapy 2015; 6: 356-361. 
28. Montero A, Hernanz R, Capuz AB et al. High-dose-rate 
(HDR) plesiotherapy with custom-made moulds for the 
treatment of non-melanoma skin cancer. Clin Transl Oncol 
2009; 11: 760-764. 
29. Maroñas M, Guinot JL, Arribas L et al. Treatment of facial 
cutaneous carcinoma with high dose rate contact brachyther-
apy with customized molds. Brachytherapy 2011; 10: 221-227. 
30. Kanikowski M. HDR brachytherapy of skin cancer in materi-
al of Greater Poland Cancer Center. J Contemp Brachytherapy 
2009; 1: 197 (Abstract). 
31. Gauden R, Pracy M, Avery AM et al. HDR brachytherapy for 
superficial non-melanoma skin cancers. Radiat Oncol 2013; 57: 
212-217. 
32. Bhatnagar A. Nonmelanoma skin cancer treated with elec-
tronic brachytherapy: results at 1 year. Brachytherapy 2013; 
12: 134-140. 
33. Jones B, Dale RG, Deehan C et al. The role of biologically 
effective dose (BED) in clinical oncology. Clin Oncol (R Coll 
Radiol) 2001; 13: 71-81. 
34. Jones B, Dale RG. Mathematical models of tumour and nor-
mal tissue response. Acta Oncol 1999; 38: 883-893. 
35. Brenner DJ, Hall EJ. Fractionation and protraction for radio-
therapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 
43: 1095-1101. 
36. Tormo A, Celada F, Rodriguez S et al. Non-melanoma skin 
cancer treated with HDR Valencia applicator: clinical out-
comes. J Contemp Brachytherapy 2014; 6: 167-172. 
